Drug intelligence / Profile preview

EMP-CNS

Development stage: Preclinical
Lead developer: Empirico
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

EMP-CNS is an investigational small interfering RNA (siRNA) therapy being developed by Empirico for the treatment of neurodegenerative diseases. The program utilizes a GalNAc-conjugated siRNA delivery platform to target a novel, undisclosed molecular pathway identified through Empirico's genetics-led drug discovery platform. By leveraging RNA interference (RNAi), EMP-CNS aims to silence the expression of a specific gene associated with neurodegeneration. As of early 2026, the program is in the IND-enabling stage of development.

Other names: EMP-CNS-Empirico-siRNA (GalNAc)-Neurodegeneration

Beyond the preview

Go deeper on EMP-CNS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP-CNS.

Explore the full profile